Inhibitor Therapeutics

(OTC) INTI

Current Price$0.08

Market Cap$14.65M

Since IPO (1997)-99%

5 Year-21%

1 Year+57%

1 Month+2%

Inhibitor Therapeutics Financials at a Glance

Market Cap

$14.65M

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.35M

EPS (TTM)

-$0.02

P/E Ratio

-4.37

Dividend

$0.00

Beta (Volatility)

-0.25 (Low)

Dividend

$0.00

Beta (Volatility)

-0.25 (Low)

Price

$0.08

Volume

15,000

Open

$0.08

Price

$0.08

Volume

15,000

Open

$0.08

Previous Close

$0.08

Daily Range

$0.08 - $0.08

52-Week Range

$0.04 - $0.12

Estimated Earnings Date

May 15, 2026

Dividend

$0.00

Beta (Volatility)

-0.25 (Low)

Price

$0.08

Volume

15,000

Open

$0.08

Previous Close

$0.08

Daily Range

$0.08 - $0.08

52-Week Range

$0.04 - $0.12

Estimated Earnings Date

May 15, 2026

INTI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Inhibitor Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Frank E. O'Donnell, Jr.

Website

www.inhibitortx.com

Headquarters

Tampa, FL 33602, US

INTI Financials

Key Financial Metrics (TTM)

Gross Margin

Operating Margin

Net Income Margin

Return on Equity

-952%

Return on Capital

-3%

Return on Assets

-2%

Earnings Yield

-22.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.65M

Shares Outstanding

172.57M

Volume

15.00K

Avg. Volume

12.12K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$3.43M

EBITDA

-$3.43M

Operating Cash Flow

-$3.23M

Capital Expenditure

$0.00

Free Cash Flow

-$3.23M

Cash & ST Invst.

$2.38M

Total Debt

$61.61K

Inhibitor Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$14.65M

N/A

Market Cap/Employee

$4.88M

N/A

Employees

N/A

Net Income

-$686.43K

-8.4%

EBITDA

-$695.63K

-3.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$1.29M

-70.1%

Total Debt

$58.36K

-30.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$29.38K

-49.7%

Short Term Debt

$28.98K

-44.2%

Return on Assets

-2.34%

N/A

Return on Invested Capital

-3.28%

N/A

Free Cash Flow

-$1.08M

+15.6%

Operating Cash Flow

-$1.08M

+15.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LIANYLianBio

LIANYLianBio$0.16+44.14%

CUBTCurative Biotechnology, Inc.

CUBTCurative Biotechnology, Inc.$1.40-9.09%

NYMXFNymox Pharmaceutical Corporation

NYMXFNymox Pharmaceutical Corporation$0.10+1.36%

BETRFBetterLife Pharma Inc.

BETRFBetterLife Pharma Inc.$0.05-4.00%

PHRRFPharmaTher Holdings Ltd.

PHRRFPharmaTher Holdings Ltd.$0.04-2.33%

NSVGFNass Valley Gateway Ltd.

NSVGFNass Valley Gateway Ltd.$0.01+0.00%

DVHGFDevonian Health Group Inc.

DVHGFDevonian Health Group Inc.$10.65+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$160.95+0.19%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

INTCIntel

INTCIntel$124.57+0.07%

NOKNokia

NOKNokia$14.80+0.05%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$40.04-0.02%

Questions About INTI

What is the current price of Inhibitor Therapeutics?

Inhibitor Therapeutics is trading at $0.08 per share.

What is the 52-week range for Inhibitor Therapeutics?

Over the past 52 weeks, Inhibitor Therapeutics has traded between $0.04 and $0.12.

How much debt does Inhibitor Therapeutics have?

As of the most recent reporting period, Inhibitor Therapeutics reported total debt of $58.36K.

How much cash does Inhibitor Therapeutics have on hand?

Inhibitor Therapeutics reported $1.29M in cash and cash equivalents in its most recent financial results.

What is Inhibitor Therapeutics’s dividend yield?

Inhibitor Therapeutics does not currently have a dividend yield.

Inhibitor Therapeutics

Inhibitor Therapeutics Financials at a Glance

INTI News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Inhibitor Therapeutics

INTI Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Inhibitor Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About INTI

What is the current price of Inhibitor Therapeutics?

What is the 52-week range for Inhibitor Therapeutics?

How much debt does Inhibitor Therapeutics have?

How much cash does Inhibitor Therapeutics have on hand?

What is Inhibitor Therapeutics’s dividend yield?

Premium Investing Services